---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-263536"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:39:59.903735+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Beam Q3 net loss $112.7M; cash $1.1B; BEAM-302 expands; Orbital acquisition by BMS

## Summary
- Net loss of $112.7M ($1.10 per share) in Q3 2025 vs $96.7M ($1.17 per share) in Q3 2024.
- Cash, cash equivalents and marketable securities $1.1B as of Sep 30, 2025, up from $850.7M at Dec 31, 2024; runway into 2028.
- BEAM-302 expanded: multi-dose cohort (60 mg x2, 8 wks apart) in Part A; first patient dosed in Part B (liver disease). Data in early 2026.
- BEAM-101 updated data accepted for ASH Dec 2025; FDA granted RMAT designation in Aug 2025.
- First subject dosed with BEAM-103 (ESCAPE mAb) in Phase 1 HV trial; BMS to acquire Orbital for $1.5B; Beam holds ~17% stake.

## SEC filing metadata
- accession: 0001193125-25-263536
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000119312525263536/0001193125-25-263536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000119312525263536/beam-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-263536
- JSON: https://secwatch.observer/filing/0001193125-25-263536.json
- Plain text: https://secwatch.observer/filing/0001193125-25-263536.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.